Advances in the understanding and treatment of sepsis-induced immunosuppression

Nature Reviews Nephrology

Volumn 14, Issue 2, 2018, Pages 121-137

  Venet, Fabienne ^a,b   Monneret, Guillaume ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b University of Lyon EA 7426 Pathophysiology of Injury Induced Immunosuppression PI3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; ENDOTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 7; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 17;

ACUTE KIDNEY FAILURE; APOPTOSIS; AUTOPHAGY; B LYMPHOCYTE; BONE MARROW; CELL MATURATION; CELL METABOLISM; CENTRAL NERVOUS SYSTEM; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSENESCENCE; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INNATE IMMUNITY; LYMPHOID CELL; LYMPHOID ORGAN; MALIGNANT NEOPLASM; MONOCYTE; MORTALITY RISK; MUCOSAL-ASSOCIATED INVARIANT T CELL; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUROMODULATION; NEUTROPHIL; NONHUMAN; NUCLEAR REPROGRAMMING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; SEPSIS; SEPSIS INDUCED IMMUNOSUPPRESSION; THYMUS; BLOOD; COMPLICATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PROGNOSIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; AUTOPHAGY; B-LYMPHOCYTES; BIOMARKERS; DENDRITIC CELLS; EPIGENESIS, GENETIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; IMMUNOSENESCENCE; INTERFERON-GAMMA; INTERLEUKIN-17; LEUKOCYTES; MONOCYTES; MYELOID-DERIVED SUPPRESSOR CELLS; NEUTROPHILS; PROGNOSIS; SEPSIS; T-LYMPHOCYTES;

EID: 85040925789     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2017.165     Document Type: Review

References (231)

1. Singer, M. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis 3). JAMA 315, 801-810 (2016).
2. Deutschman, C. S. & Tracey, K. J. Sepsis: current dogma and new perspectives. Immunity 40, 463-475 (2014).
3. Hotchkiss, R. S. et al. Sepsis and septic shock. Nat. Rev. Dis. Primers 2, 16045 (2016).
4. Reinhart, K. et al. Recognizing sepsis as a global health priority - a WHO resolution. N. Engl. J. Med. 377, 414-417 (2017).
5. van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P. & Netea, M. G. The immunopathology of sepsis and potential therapeutic targets. Nat. Rev. Immunol. 17, 407-420 (2017).
6. Zeni, F., Freeman, B. & Natanson, C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25, 1095-1100 (1997).
7. Hotchkiss, R. S., Monneret, G. & Payen, D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13, 260-268 (2013).
8. Hotchkiss, R. S., Monneret, G. & Payen, D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 13, 862-874 (2013).
9. Meakins, J. L. et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann. Surg. 186, 241-250 (1977).
10. Christou, N. V. et al. The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann. Surg. 222, 534-548 (1995).
11. Munoz, C. et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88, 1747-1754 (1991).
12. Hotchkiss, R. S. et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27, 1230-1251 (1999).
13. Hotchkiss, R. S. et al. Rapid onset of intestinal epithelial and lymphocyte apoptotic cell death in patients with trauma and shock. Crit. Care Med. 28, 3207-3217 (2000).
14. Bone, R. C., Grodzin, C. J. & Balk, R. A. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112, 235-243 (1997).
15. Docke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3, 678-681 (1997).
16. Munford, R. S. & Pugin, J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med. 163, 316-321 (2001).
17. Hotchkiss, R. S. & Nicholson, D. W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6, 813-822 (2006).
18. Hotchkiss, R. S. et al. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc. Natl Acad. Sci. USA 100, 6724-6729 (2003).
19. Ayala, A. et al. Apoptosis in sepsis: mechanisms, clinical impact and potential therapeutic targets. Curr. Pharm. Des. 14, 1853-1859 (2008).
20. Hotchkiss, R. S., Coopersmith, C. M. & Karl, I. E. Prevention of lymphocyte apoptosis - a potential treatment of sepsis? Clin. Infect. Dis. 41 (Suppl. 7), S465-S469 (2005).
21. Jorgensen, I., Rayamajhi, M. & Miao, E. A. Programmed cell death as a defence against infection. Nat. Rev. Immunol. 17, 151-164 (2017).
22. Cadwell, K. Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis. Nat. Rev. Immunol. 16, 661-675 (2016).
23. Hsieh, Y. C., Athar, M. & Chaudry, I. H. When apoptosis meets autophagy: deciding cell fate after trauma and sepsis. Trends Mol. Med. 15, 129-138 (2009).
24. Lin, C. W. et al. T Cell autophagy deficiency increases mortality and suppresses immune responses after sepsis. PLoS ONE 9, e102066 (2014).
25. Oami, T. et al. Suppression of T cell autophagy results in decreased viability and function of T cells through accelerated apoptosis in a murine sepsis model. Crit. Care Med. 45, e77-e85 (2017).
26. Seeley, J. J. & Ghosh, S. Molecular mechanisms of innate memory and tolerance to LPS. J. Leukoc. Biol. 101, 107-119 (2017).
27. Biswas, S. K. & Lopez-Collazo, E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30, 475-487 (2009).
28. Wolk, K., Docke, W. D., von Baehr, V., Volk, H. D. & Sabat, R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96, 218-223 (2000).
29. Shalova, I. N. et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor 1α. Immunity 42, 484-498 (2015).
30. Allantaz-Frager, F. et al. Identification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shock. PLoS ONE 8, e68218 (2013).
31. Morris, M. C., Gilliam, E. A. & Li, L. Innate immune programing by endotoxin and its pathological consequences. Front. Immunol. 5, 680 (2015).
32. van't Veer, C. et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J. Immunol. 179, 7110-7120 (2007).
33. Sfeir, T., Saha, D. C., Astiz, M. & Rackow, E. C. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit. Care Med. 29, 129-133 (2001).
34. Novakovic, B. et al. β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354-1368.e14 (2016).
35. Muller, M. M. et al. Global analysis of glycoproteins identifies markers of endotoxin tolerant monocytes and GPR84 as a modulator of TNFα expression. Sci. Rep. 7, 838 (2017).
36. Hoogendijk, A. J. et al. Sepsis patients display a reduced capacity to activate nuclear factor-κB in multiple cell types. Crit. Care Med. 45, e524-e531 (2017).
37. Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).
38. Chavan, S. S. & Tracey, K. J. Essential neuroscience in immunology. J. Immunol. 198, 3389-3397 (2017).
39. Sternberg, E. M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6, 318-328 (2006).
40. Dalli, J., Colas, R. A., Arnardottir, H. & Serhan, C. N. Vagal regulation of group 3 innate lymphoid cells and the immunoresolvent PCTR1 controls infection resolution. Immunity 46, 92-105 (2017).
41. Singer, B. H. et al. Cecal ligation and puncture results in long-term central nervous system myeloid inflammation. PLoS ONE 11, e0149136 (2016).
42. Martelli, D., Yao, S. T., McKinley, M. J. & McAllen, R. M. Reflex control of inflammation by sympathetic nerves, not the vagus. J. Physiol. 592, 1677-1686 (2014).
43. Stolk, R. F. et al. Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am. J. Respir. Crit. Care Med. 194, 550-558 (2016).
44. MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259-283 (2013).
45. Stienstra, R., Netea-Maier, R. T., Riksen, N. P., Joosten, L. A. B. & Netea, M. G. Specific and complex reprogramming of cellular metabolism in myeloid cells during innate immune responses. Cell Metab. 26, 142-156 (2017).
46. Arts, R. J., Gresnigt, M. S., Joosten, L. A. & Netea, M. G. Cellular metabolism of myeloid cells in sepsis. J. Leukoc. Biol. 101, 151-164 (2017).
47. Cheng, S. C. et al. mTOR- and HIF 1α mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).
48. Cheng, S. C. et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat. Immunol. 17, 406-413 (2016).
49. Venet, F. et al. IL 7 restores T lymphocyte immunometabolic failure in septic shock patients through mTOR activation. J. Immunol. 199, 1606-1615 (2017).
50. Edwards, M. R. et al. Metabolic dysfunction in lymphocytes promotes postoperative morbidity. Clin. Sci. 129, 423-437 (2015).
51. Singer, M., De Santis, V., Vitale, D. & Jeffcoate, W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 364, 545-548 (2004).
52. Cazalis, M. A. et al. Early and dynamic changes in gene expression in septic shock patients: a genome-wide approach. Intensive Care Med. Exp. 2, 20 (2014).
53. Xiao, W. et al. A genomic storm in critically injured humans. J. Exp. Med. 208, 2581-2590 (2011).
54. Davenport, E. E. et al. Genomic landscape of the individual host response and outcomes in sepsis: aprospective cohort study. Lancet Respir. Med. 4, 259-271 (2016).
55. Carson, W. F., Cavassani, K. A., Dou, Y. & Kunkel, S. L. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 6, 273-283 (2011).
56. Leentjens, J., Kox, M., van der Hoeven, J. G., Netea, M. G. & Pickkers, P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am. J. Respir. Crit. Care Med. 187, 1287-1293 (2013).
57. El Gazzar, M. et al. Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol. Cell. Biol. 29, 1959-1971 (2009).
58. El Gazzar, M., Liu, T., Yoza, B. K. & McCall, C. E. Dynamic and selective nucleosome repositioning during endotoxin tolerance. J. Biol. Chem. 285, 1259-1271 (2010).
59. Wen, H., Dou, Y., Hogaboam, C. M. & Kunkel, S. L. Epigenetic regulation of dendritic cell-derived interleukin 12 facilitates immunosuppression after a severe innate immune response. Blood 111, 1797-1804 (2008).
60. + T cell proliferation and effector function correlates with repressive histone methylation events in a mouse model of severe sepsis. Eur. J. Immunol. 40, 998-1010 (2010).
61. Cavassani, K. A. et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 115, 4403-4411 (2010).
62. El Gazzar, M. & McCall, C. E. MicroRNAs distinguish translational from transcriptional silencing during endotoxin tolerance. J. Biol. Chem. 285, 20940-20951 (2010).
63. Vachharajani, V. T. et al. Sirtuins link inflammation and metabolism. J. Immunol. Res. 2016, 8167273 (2016).
64. +-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J. Biol. Chem. 286, 9856-9864 (2011).
65. Opal, S. M. et al. Pharmacological Sirt1 activation improves mortality and markedly alters transcriptional profiles that accompany experimental sepsis. Shock 45, 411-418 (2016).
66. Guerin, E. et al. Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration∗. Crit. Care Med. 42, 2007-2018 (2014).
67. Pillay, J. et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac 1. J. Clin. Invest. 122, 327-336 (2012).
68. Demaret, J. et al. Marked alterations of neutrophil functions during sepsis-induced immunosuppression. J. Leukoc. Biol. 98, 1081-1090 (2015).
69. Hampson, P. et al. Neutrophil dysfunction, immature granulocytes, and cell-free DNA are early biomarkers of sepsis in burn-injured patients: a prospective observational cohort study. Ann. Surg. 265, 1241-1249 (2016).
70. Groeneveld, K. M. et al. Early decreased neutrophil responsiveness is related to late onset sepsis in multitrauma patients: an international cohort study. PLoS ONE 12, e0180145 (2017).
71. Gregoire, M. et al. Frontline Science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. J. Leukoc. Biol. 101, 1281-1287 (2017).
72. Huang, X. et al. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J. Immunol. 192, 1091-1099 (2014).
73. Gabrilovich, D. I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3-8 (2017).
74. Ost, M. et al. Myeloid-derived suppressor cells in bacterial infections. Front. Cell. Infect. Microbiol. 6, 37 (2016).
75. + population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204, 1463-1474 (2007).
76. Brudecki, L., Ferguson, D. A., McCall, C. E. & El Gazzar, M. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect. Immun. 80, 2026-2034 (2012).
77. Albertsmeier, M. et al. Monocyte-dependent suppression of T-cell function in postoperative patients and abdominal sepsis. Shock 48, 651-656 (2017).
78. McPeak, M. B. et al. Myeloid cell-specific knockout of NFI A improves sepsis survival. Infect. Immun. 85, e00066 17 (2017).
79. McPeak, M. B. et al. Frontline Science: Myeloid cell-specific deletion of Cebpb decreases sepsis-induced immunosuppression in mice. J. Leukoc. Biol. 102, 191-200 (2017).
80. + cells from lipopolysaccharide-immunosuppressed mice acquire inhibitory activity in the bone marrow and migrate to lymph nodes to exert their suppressive function. Clin. Sci. 130, 259-271 (2016).
81. Llitjos, J. F. et al. Sepsis-induced expansion of granulocytic myeloid-derived suppressor cells promotes tumour growth through Toll-like receptor 4. J. Pathol. 239, 473-483 (2016).
82. Mathias, B. et al. Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock. Ann. Surg. 265, 827-834 (2016).
83. Janols, H. et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J. Leukoc. Biol. 96, 685-693 (2014).
84. Uhel, F. et al. Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in septic patients. Am. J. Respir. Crit. Care Med. 196, 315-327 (2017).
85. Dumitru, C. A., Moses, K., Trellakis, S., Lang, S. & Brandau, S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 61, 1155-1167 (2012).
86. Monneret, G. & Venet, F. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy. Cytom. B Clin. Cytom 90, 376-386 (2015).
87. Venet, F., Lukaszewicz, A. C., Payen, D., Hotchkiss, R. & Monneret, G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr. Opin. Immunol. 25, 477-483 (2013).
88. Galbraith, N., Walker, S., Carter, J. & Polk, H. C. Jr. Past, present, and future of augmentation of monocyte function in the surgical patient. Surg. Infect. 17, 563-569 (2016).
89. Guignant, C. et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit. Care 15, R99 (2011).
90. Zhang, Y. et al. Upregulation of programmed death 1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit. Care 15, R70 (2011).
91. Shao, R. et al. Monocyte programmed death ligand 1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit. Care 20, 124 (2016).
92. - myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut http://dx.doi.org/10.1136/gutjnl-2017-314184 (2017).
93. Roquilly, A. & Villadangos, J. A. The role of dendritic cell alterations in susceptibility to hospital-acquired infections during critical-illness related immunosuppression. Mol. Immunol. 68, 120-123 (2015).
94. Guisset, O. et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med. 33, 148-152 (2007).
95. Grimaldi, D. et al. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med. 37, 1438-1446 (2011).
96. Wen, H., Schaller, M. A., Dou, Y., Hogaboam, C. M. & Kunkel, S. L. Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. J. Leukoc. Biol. 83, 439-446 (2008).
97. Strother, R. K. et al. Polymicrobial sepsis diminishes dendritic cell numbers and function directly contributing to impaired primary CD8 T cell responses In Vivo. J. Immunol. 197, 4301-4311 (2016).
98. Meng, Y. et al. CD155 blockade improves survival in experimental sepsis by reversing dendritic cell dysfunction. Biochem. Biophys. Res. Commun. 490, 283-289 (2017).
99. Huang, X., Venet, F., Chung, C. S., Lomas-Neira, J. & Ayala, A. Changes in dendritic cell function in the immune response to sepsis. Cell- and tissue-based therapy. Expert Opin. Biol. Ther. 7, 929-938 (2007).
100. Roquilly, A. et al. Local modulation of antigen-presenting cell development after resolution of pneumonia induces long-term susceptibility to secondary infections. Immunity 47, 135-147.e5 (2017).
101. Venet, F. et al. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 34, 358-363 (2010).
102. Le Tulzo, Y. et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 18, 487-494 (2002).
103. Drewry, A. M. et al. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock 42, 383-391 (2014).
104. Chung, K. P. et al. Severe lymphopenia is associated with elevated plasma interleukin-15 levels and increased mortality during severe sepsis. Shock 43, 569-575 (2015).
105. Adrie, C. et al. Persistent lymphopenia is a risk factor for ICU-acquired infections and for death in ICU patients with sustained hypotension at admission. Ann. Intensive Care 7, 30 (2017).
106. Souza-Fonseca-Guimaraes, F., Parlato, M., Fitting, C., Cavaillon, J. M. & Adib-Conquy, M. NK cell tolerance to TLR agonists mediated by regulatory T cells after polymicrobial sepsis. J. Immunol. 188, 5850-5858 (2012).
107. Deknuydt, F., Roquilly, A., Cinotti, R., Altare, F. & Asehnoune, K. An in vitro model of mycobacterial granuloma to investigate the immune response in brain-injured patients. Crit. Care Med. 41, 245-254 (2013).
108. Patera, A. C. et al. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J. Leukoc. Biol. 100, 1239-1254 (2016).
109. Hou, H. et al. Tim 3 negatively mediates natural killer cell function in LPS-induced endotoxic shock. PLoS ONE 9, e110585 (2014).
110. Shindo, Y. et al. Anti PD L1 peptide improves survival in sepsis. J. Surg. Res. 208, 33-39 (2017).
111. Chiche, L. et al. Interferon-gamma production by natural killer cells and cytomegalovirus in critically ill patients. Crit. Care Med. 40, 3162-3169 (2012).
112. Wong, C. H., Jenne, C. N., Lee, W. Y., Leger, C. & Kubes, P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science 334, 101-105 (2011).
113. Shindo, Y. et al. Interleukin 7 immunotherapy improves host immunity and survival in a two-hit model of Pseudomonas aeruginosa pneumonia. J. Leukoc. Biol. 101, 543-554 (2017).
114. Grimaldi, D. et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med. 40, 192-201 (2014).
115. Mohr, A. et al. Sepsis leads to a reduced antigen-specific primary antibody response. Eur. J. Immunol. 42, 341-352 (2012).
116. Kelly-Scumpia, K. M. et al. B cells enhance early innate immune responses during bacterial sepsis. J. Exp. Med. 208, 1673-1682 (2011).
117. Rauch, P. J. et al. Innate response activator B cells protect against microbial sepsis. Science 335, 597-601 (2012).
118. Weber, G. F. et al. Interleukin 3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347, 1260-1265 (2015).
119. Aziz, M., Holodick, N. E., Rothstein, T. L. & Wang, P. B-1a cells protect mice from sepsis: critical role of CREB. J. Immunol. 199, 750-760 (2017).
120. Mauri, C. & Menon, M. Human regulatory B cells in health and disease: therapeutic potential. J. Clin. Invest. 127, 772-779 (2017).
121. Shankar-Hari, M. et al. Activation-associated accelerated apoptosis of memory B cells in critically ill patients with sepsis. Crit. Care Med. 45, 875-882 (2017).
122. Suzuki, K. et al. Reduced immunocompetent B cells and increased secondary infection in elderly patients with severe sepsis. Shock 46, 270-278 (2016).
123. Giamarellos-Bourboulis, E. J. et al. Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit. Care 17, R247 (2013).
124. hi regulatory B cells in neonatal sepsis patients and its functional implication. Med. Sci. Monit. 22, 2374-2378 (2016).
125. Cabrera-Perez, J., Condotta, S. A., Badovinac, V. P. & Griffith, T. S. Impact of sepsis on CD4 T cell immunity. J. Leukoc. Biol. 96, 767-777 (2014).
126. Danahy, D. B., Strother, R. K., Badovinac, V. P. & Griffith, T. S. Clinical and experimental sepsis impairs CD8 T-cell-mediated immunity. Crit. Rev. Immunol. 36, 57-74 (2016).
127. Boomer, J. S. et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306, 2594-2605 (2011).
128. Spec, A. et al. T cells from patients with Candida sepsis display a suppressive immunophenotype. Crit. Care 20, 15 (2016).
129. Demaret, J. et al. STAT5 phosphorylation in T cell subsets from septic patients in response to recombinant human interleukin-7: a pilot study. J. Leukoc. Biol. 97, 791-796 (2015).
130. H2 skewing. Anesthesiology 124, 908-922 (2016).
131. Boomer, J. S., Shuherk-Shaffer, J., Hotchkiss, R. S. & Green, J. M. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit. Care 16, R112 (2012).
132. Venet, F. et al. Decreased T cell repertoire diversity in sepsis: a preliminary study. Crit. Care Med. 41, 111-119 (2013).
133. -) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 35, 678-686 (2009).
134. Venet, F. et al. Regulatory T cell populations in sepsis and trauma. J. Leukoc. Biol. 83, 523-535 (2008).
135. Nascimento, D. C. et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit. Care Med. 38, 1718-1725 (2010).
136. + regulatory T cells predict poor survival for sepsis patients. Int. J. Infect. Dis. 30, 57-63 (2014).
137. Nascimento, D. C. et al. IL 33 contributes to sepsis-induced long-term immunosuppression by expanding the regulatory T cell population. Nat. Commun. 8, 14919 (2017).
138. + T lymphocytes in humans. J. Immunol. 166, 6952-6963 (2001).
139. Felmet, K. A., Hall, M. W., Clark, R. S., Jaffe, R. & Carcillo, J. A. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J. Immunol. 174, 3765-3772 (2005).
140. Muehlstedt, S. G., Lyte, M. & Rodriguez, J. L. Increased IL-10 production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock 17, 443-450 (2002).
141. Chalk, K. et al. Dysfunction of alveolar macrophages after cardiac surgery and postoperative pneumonia? - An observational study. Crit. Care 17, R285 (2013).
142. Faivre, V., Lukaszewicz, A. C. & Payen, D. Downregulation of blood monocyte HLA-DR in ICU patients is also present in bone marrow cells. PLoS ONE 11, e0164489 (2016).
143. Skirecki, T. et al. Early severe impairment of hematopoietic stem and progenitor cells from the bone marrow caused by CLP sepsis and endotoxemia in a humanized mice model. Stem Cell Res. Ther. 6, 142 (2015).
144. Rodriguez, S. et al. Dysfunctional expansion of hematopoietic stem cells and block of myeloid differentiation in lethal sepsis. Blood 114, 4064-4076 (2009).
145. Netzer, C. et al. Apoptotic diminution of immature single and double positive thymocyte subpopulations contributes to thymus involution during murine polymicrobial sepsis. Shock 48, 215-226 (2017).
146. Kong, Y. et al. Sepsis-induced thymic atrophy is associated with defects in early lymphopoiesis. Stem Cells 34, 2902-2915 (2016).
147. Gruver, A. L., Ventevogel, M. S. & Sempowski, G. D. Leptin receptor is expressed in thymus medulla and leptin protects against thymic remodeling during endotoxemia-induced thymus involution. J. Endocrinol. 203, 75-85 (2009).
148. Torgersen, C. et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth. Analg 108, 1841-1847 (2009).
149. Landelle, C. et al. Nosocomial infection after septic shock among intensive care unit patients. Infect. Control Hosp. Epidemiol. 29, 1054-1065 (2008).
150. van Vught, L. A. et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315, 1469-1479 (2016).
151. Koch, R. M. et al. Patterns in bacterial- and viral-induced immunosuppression and secondary infections in the ICU. Shock 47, 5-12 (2017).
152. Monneret, G., Venet, F., Kullberg, B. J. & Netea, M. G. ICU-acquired immunosuppression and the risk for secondary fungal infections. Med. Mycol. 49 (Suppl. 1), S17-S23 (2011).
153. Segal, B. H. Aspergillosis. N. Engl. J. Med. 360, 1870-1884 (2009).
154. Walton, A. H. et al. Reactivation of multiple viruses in patients with sepsis. PLoS ONE 9, e98819 (2014).
155. Ong, D. S. Y. et al. Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock. Clin. Infect. Dis. 64, 1204-1210 (2017).
156. Luyt, C. E., Combes, A., Nieszkowska, A., Trouillet, J. L. & Chastre, J. Viral infections in the ICU. Curr. Opin. Crit. Care 14, 605-608 (2008).
157. Ong, D. S. et al. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 42, 333-341 (2016).
158. Kalil, A. C. & Florescu, D. F. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit. Care Med. 37, 2350-2358 (2009).
159. Chiche, L. et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit. Care Med. 37, 1850-1857 (2009).
160. Ong, D. S. et al. Cytomegalovirus seroprevalence as a risk factor for poor outcome in acute respiratory distress syndrome∗. Crit. Care Med. 43, 394-400 (2015).
161. Kalil, A. C., Sun, J. & Florescu, D. F. The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis. Crit. Care Med. 38, S663-667 (2010).
162. Goodwin, A. J., Rice, D. A., Simpson, K. N. & Ford, D. W. Frequency, cost, and risk factors of readmissions among severe sepsis survivors. Crit. Care Med. 43, 738-746 (2015).
163. Prescott, H. C., Langa, K. M., Liu, V., Escobar, G. J. & Iwashyna, T. J. Increased 1-year healthcare use in survivors of severe sepsis. Am. J. Respir. Crit. Care Med. 190, 62-69 (2014).
164. Shankar-Hari, M. & Rubenfeld, G. D. Understanding long-term outcomes following sepsis: implications and challenges. Curr. Infect. Dis. Rep. 18, 37 (2016).
165. Chang, D. W., Tseng, C. H. & Shapiro, M. F. Rehospitalizations following sepsis: common and costly. Crit. Care Med. 43, 2085-2093 (2015).
166. Ortego, A. et al. Hospital-based acute care use in survivors of septic shock. Crit. Care Med. 43, 729-737 (2015).
167. Prescott, H. C., Osterholzer, J. J., Langa, K. M., Angus, D. C. & Iwashyna, T. J. Late mortality after sepsis: propensity matched cohort study. BMJ 353, i2375 (2016).
168. Sun, A. et al. Association between index hospitalization and hospital readmission in sepsis survivors. Crit. Care Med. 44, 478-487 (2016).
169. Wang, H. E. et al. Long-term mortality after community-acquired sepsis: a longitudinal population-based cohort study. BMJ Open 4, e004283 (2014).
170. Linder, A. et al. Long-term (10-year) mortality of younger previously healthy patients with severe sepsis/septic shock is worse than that of patients with nonseptic critical illness and of the general population. Crit. Care Med. 42, 2211-2218 (2014).
171. Mira, J. C. et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit. Care Med. 45, 253-262 (2017).
172. Delano, M. J. & Ward, P. A. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J. Clin. Invest. 126, 23-31 (2016).
173. Nomellini, V., Kaplan, L. J., Sims, C. A. & Caldwell, C. C. Chronic critical illness and persistent inflammation: what can we learn from the elderly, injured, septic, and malnourished? Shock http://dx.doi.org/10.1097/SHK.0000000000000939 (2017).
174. Zorio, V. et al. Assessment of sepsis-induced immunosuppression at ICU discharge and 6 months after ICU discharge. Ann. Intensive Care 7, 80 (2017).
175. Yende, S. & Angus, D. C. Long-term outcomes from sepsis. Curr. Infect. Dis. Rep. 9, 382-386 (2007).
176. Arens, C. et al. Sepsis-induced long-term immune paralysis - results of a descriptive, explorative study. Crit. Care 20, 93 (2016).
177. Borken, F. et al. Chronic critical illness from sepsis is associated with an enhanced TCR response. J. Immunol. 198, 4781-4791 (2017).
178. Oliveira, N. M. et al. Sepsis induces telomere shortening: a potential mechanism responsible for delayed pathophysiological events in sepsis survivors? Mol. Med. http://dx.doi.org/10.2119/molmed.2016.00225 (2016).
179. Nguyen, V., Mendelsohn, A. & Larrick, J. W. Interleukin 7 and immunosenescence. J. Immunol. Res. 2017, 4807853 (2017).
180. Chaudhry, M. S., Velardi, E., Dudakov, J. A. & van den Brink, M. R. Thymus: the next (re)generation. Immunol. Rev. 271, 56-71 (2016).
181. Shakoory, B. et al. Interleukin 1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 44, 275-281 (2016).
182. Panacek, E. A. et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32, 2173-2182 (2004).
183. Eichacker, P. Q. et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205 (2002).
184. Benjamim, C. F., Lundy, S. K., Lukacs, N. W., Hogaboam, C. M. & Kunkel, S. L. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 105, 3588-3595 (2005).
185. Unsinger, J. et al. Interleukin 7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J. Infect. Dis. 206, 606-616 (2012).
186. Dyck, L. & Mills, K. H. G. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur. J. Immunol. 47, 765-779 (2017).
187. Hotchkiss, R. S. & Moldawer, L. L. Parallels between cancer and infectious disease. N. Engl. J. Med. 371, 380-383 (2014).
188. Shekarian, T. et al. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann. Oncol. 28, 1756-1766 (2017).
189. Roquilly, A. et al. TLR 4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. Eur. Respir. J. 42, 1365-1378 (2013).
190. Davis, C. G. et al. TLR3 agonist improves survival to secondary pneumonia in a double injury model. J. Surg. Res. 182, 270-276 (2013).
191. Chen, G. H. et al. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J. Immunol. 165, 6496-6503 (2000).
192. Wu, J. et al. The efficacy of thymosin alpha 1 for severesepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care 17, R8 (2013).
193. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02867267 (2017).
194. Hutchins, N. A., Unsinger, J., Hotchkiss, R. S. & Ayala, A. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol. Med. 20, 224-233 (2014).
195. Nakos, G. et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit. Care Med. 30, 1488-1494 (2002).
196. Nalos, M. et al. Immune effects of interferon gamma in persistent staphylococcal sepsis. Am. J. Respir. Crit. Care Med. 185, 110-112 (2012).
197. Lukaszewicz, A. C. et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit. Care Med. 37, 2746-2752 (2009).
198. Delsing, C. E. et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect. Dis. 14, 166 (2014).
199. Grimaldi, D., Pradier, O., Hotchkiss, R. S. & Vincent, J. L. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. Lancet Infect. Dis. 17, 18 (2017).
200. Cutino-Moguel, M. T., Eades, C., Rezvani, K. & Armstrong-James, D. Immunotherapy for infectious diseases in haematological immunocompromise. Br. J. Haematol. 177, 348-356 (2017).
201. Hall, M. W. et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37, 525-532(2011).
202. Nelson, L. A. Use of granulocyte-macrophage colony-stimulating factor to reverse anergy in otherwise immunologically healthy children. Ann. Allergy Asthma Immunol. 98, 373-382 (2007).
203. Drossou-Agakidou, V. et al. In vivo effect of rhGM-CSF And rhG-CSF on monocyte HLA-DR expression of septic neonates. Cytokine 18, 260-265 (2002).
204. Protti, A. et al. Granulocyte-macrophage colony stimulating factor for non-resolving legionellosis. Anaesth. Intensive Care 42, 804-806 (2014).
205. Meisel, C. et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180, 640-648 (2009).
206. Mathias, B., Szpila, B. E., Moore, F. A., Efron, P. A. & Moldawer, L. L. A. Review of GM-CSF therapy in sepsis. Medicine 94, e2044 (2015).
207. US National Library of Medicine. ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT02361528 (2016).
208. Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11, 330-342 (2011).
209. Lundstrom, W., Fewkes, N. M. & Mackall, C. L. IL 7 in human health and disease. Semin. Immunol. 24, 218-224 (2012).
210. Terashima, A. et al. Sepsis-induced osteoblast ablation causes immunodeficiency. Immunity 44, 1434-1443(2016).
211. Venet, F. et al. IL 7 restores lymphocyte functions in septic patients. J. Immunol. 189, 5073-5081 (2012).
212. Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD 1 blockade. Science 354, 1160-1165 (2016).
213. Shindo, Y., Unsinger, J., Burnham, C. A., Green, J. M. & Hotchkiss, R. S. Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock 43, 334-343 (2015).
214. Yang, Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 125, 3335-3337 (2015).
215. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02797431 (2017).
216. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02640807 (2017).
217. Chang, K. et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit. Care 18, R3 (2014).
218. Chang, K. C. et al. Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit. Care 17, R85 (2013).
219. Brahmamdam, P. et al. Delayed administration of anti PD 1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukoc. Biol. 88, 233-240 (2010).
220. Zhang, Y. et al. PD L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit. Care 14, R220 (2010).
221. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02960854 (2017).
222. US National Library of Medicine. ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02576457 (2017).
223. Cohen, J. et al. Sepsis: a roadmap for furure research Lancet Infect. Dis. 15, 581-614 (2015).
224. Perner, A. et al. The intensive care medicine research agenda on septic shock. Intensive Care Med. 43, 1294-1305 (2017).
225. Monneret, G., Venet, F., Pachot, A. & Lepape, A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol. Med. 14, 64-78 (2008).
226. Peronnet, E. et al. Association between mRNA expression of CD74 and IL10 and risk of ICU-acquired infections: a multicenter cohort study. Intensive Care Med. 43, 1013-1020 (2017).
227. Sprung, C. L. et al. Comparison of cd64 levels performed by the facs and accellix systems. Intensive Care Med Exp 3 (Suppl. 1), A1012 (2015).
228. Zouiouich, M., Gossez, M., Venet, F., Rimmele, T. & Monneret, G. Automated bedside flow cytometer for mHLA DR expression measurement: a comparison study with reference protocol. Intensive Care Med. Exp. 5, 39 (2017).
229. Monneret, G. et al. Novel approach in monocyte intracellular TNF measurement: application to sepsis-induced immune alterations. Shock 47, 318-322(2016).
230. Letessier, W. et al. Decreased intra-lymphocyte cytokines measurement in septic shock patients: a proof of concept study in whole blood. Cytokine http://dx.doi.org/10.1016/j.cyto.2017.09.029 (2017).
231. Rol, M. L. et al. The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patients. BMJ Open 7, e015734(2017).